EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Subsequent correlated changes in complement component 3 and amyloid beta oligomers in the blood of patients with Alzheimer's disease

Kyu Hwan Shim, Danyeong Kim, Min Ju Kang, Jung-Min Pyun, Young Ho Park, Young Chul Youn, Kyung Won Park, Kyoungho Suk, Ho-Won Lee, Bárbara Fernandes Gomes, Henrik Zetterberg, Seong Soo A An iD und 2 weitere

Alzheimer's & Dementia · 2024

DOI: 10.1002/alz.13734 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2024. Verfasst von Kyu Hwan Shim und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bionano Technology, Gachon University, Seongnam, Republic of Korea. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The National Research Foundation of Korea, European Union's Horizon Europe research and innovation programme, Swedish State Support for Clinical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Alzheimer's disease (AD) involves the complement cascade, with complement component 3 (C3) playing a key role. However, the relationship between C3 and amyloid beta (Aβ) in blood is limited. METHODS Plasma C3 and Aβ oligomerization tendency (AβOt) were measured in 35 AD patients and 62 healthy controls. Correlations with cerebrospinal fluid (CSF) biomarkers, cognitive impairment, and amyloid positron emission tomography (PET) were analyzed. Differences between biomarkers were compared in groups classified by concordances of biomarkers. RESULTS Plasma C3 and AβOt were elevated in AD patients and in CSF or amyloid PET–positive groups. Weak positive correlation was found between C3 and AβOt, while both had strong negative correlations with CSF Aβ 42 and cognitive performance. Abnormalities were observed for AβOt and CSF Aβ 42 followed by C3 changes. DISCUSSION Increased plasma C3 in AD are associated with amyloid pathology, possibly reflecting a defense response for Aβ clearance. Further studies on Aβ‐binding proteins will enhance understanding of Aβ mechanisms in blood.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseHumansAmyloidAmyloid beta-PeptidesBiomarkersComplement C3Peptide FragmentsPositron-Emission Tomographytau ProteinsAmyloid beta-Protein Precursor

Stichwörter der Autor:innen

Alzheimer's diseaseamyloid betabiomarkercomplement component 3oligomerplasma

Substanzen

AmyloidAmyloid beta-PeptidesBiomarkersComplement C3Peptide Fragmentstau ProteinsAPP protein, humanAmyloid beta-Protein PrecursorC3 protein, human

Autor:innen und Institutionen

  • Department of Bionano Technology, Gachon University, Seongnam, Republic of Korea.
  • Department of Neurology, Veterans Medical Research Institute, Veterans Health Service Medical Center, Seoul, Republic of Korea.
  • Department of Neurology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Republic of Korea.
  • Department of Neurology, Seoul National University College of Medicine and Clinical Neuroscience Center, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
  • Department of Neurology, Chung-Ang University College of Medicine, Seoul, Republic of Korea.
  • Department of Neurology, Dong-A University College of Medicine and Institute of Convergence Bio-Health, Busan, Republic of Korea.

ORCID-Profile: Seong Soo A An

Förderung

  • The National Research Foundation of Korea
  • European Union's Horizon Europe research and innovation programme
  • Swedish State Support for Clinical Research
  • Alzheimer Drug Discovery Foundation (ADDF), USA
  • The AD Strategic Fund and the Alzheimer's Association
  • The Bluefield Project, the Olav Thon Foundation, the Erling-Persson Family Foundation, Stiftelsen för Gamla Tjänarinnor, Hjärnfonden, Sweden
  • The European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant
  • European Union Joint Programme - Neurodegenerative Disease Research

Zitieren

APA

Shim, K. H., Kim, D., Kang, M. J., Pyun, J. M., Park, Y. H., Youn, Y. C., Park, K. W., Suk, K., Lee, H. W., Gomes, B. F., Zetterberg, H., An, S. S. A., Kim, S., & Alzheimer's Disease All Markers (ADAM) Research group (2024). Subsequent correlated changes in complement component 3 and amyloid beta oligomers in the blood of patients with Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1002/alz.13734

Vancouver

Shim KH, Kim D, Kang MJ, Pyun JM, Park YH, Youn YC, et al. Subsequent correlated changes in complement component 3 and amyloid beta oligomers in the blood of patients with Alzheimer's disease. Alzheimer's & Dementia. 2024. doi:10.1002/alz.13734

BibTeX
@article{Shim2024,
  author = {Shim, Kyu Hwan and Kim, Danyeong and Kang, Min Ju and Pyun, Jung-Min and Park, Young Ho and Youn, Young Chul and Park, Kyung Won and Suk, Kyoungho and Lee, Ho-Won and Gomes, Bárbara Fernandes and Zetterberg, Henrik and An, Seong Soo A and Kim, SangYun and Alzheimer's Disease All Markers (ADAM) Research group, Alzheimer's Disease All Markers (ADAM) Research group},
  title = {Subsequent correlated changes in complement component 3 and amyloid beta oligomers in the blood of patients with Alzheimer's disease},
  journal = {Alzheimer's & Dementia},
  year = {2024},
  doi = {10.1002/alz.13734}
}
Kostenlos starten →